- Report
- January 2024
- 93 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- March 2024
- 194 Pages
Global
From €3283EUR$3,374USD£2,812GBP
€3648EUR$3,749USD£3,125GBP
- Report
- March 2024
- 175 Pages
Global
From €4865EUR$5,000USD£4,168GBP
- Report
- February 2024
- 135 Pages
Global
From €4622EUR$4,750USD£3,959GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1216EUR$1,250USD£1,042GBP
- Report
- April 2018
Global
From €973EUR$1,000USD£834GBP
- Report
- February 2023
- 83 Pages
Asia Pacific
From €1459EUR$1,500USD£1,250GBP
- Drug Pipelines
- March 2021
Global
From €1946EUR$2,000USD£1,667GBP
- Report
- April 2023
- 95 Pages
Global
€3405EUR$3,500USD£2,917GBP
- Report
- January 2024
- 89 Pages
Global
From €3500EUR$3,853USD£3,103GBP
- Report
- November 2021
- 600 Pages
Global
From €3892EUR$4,000USD£3,334GBP
Sumatriptan is a drug used to treat migraine headaches. It is a member of the triptan class of drugs, which are serotonin receptor agonists. Sumatriptan works by narrowing the blood vessels around the brain, reducing inflammation and relieving pain. It is available in both oral and injectable forms, and is often used in combination with other medications.
Sumatriptan is a popular drug in the Central Nervous System (CNS) drug market. It is used to treat a variety of conditions, including migraine headaches, cluster headaches, and tension headaches. It is also used to treat other conditions such as fibromyalgia and chronic pain. Sumatriptan is generally well-tolerated and has few side effects.
Some companies in the Sumatriptan market include GlaxoSmithKline, Pfizer, Merck, and Novartis. Show Less Read more
